Dr. Stephen Freedman Joins Ingenium Pharmaceuticals As Executive Vice President, Corporate Development

MUNICH, Germany, Nov. 27 /PRNewswire/ -- Ingenium Pharmaceuticals AG announced today that Stephen Freedman, Ph.D., has joined the company as Executive Vice President, Corporate Development. Dr. Freedman's responsibilities will include the strategic development of Ingenium's growing pipeline of pain and chronic inflammatory disease drug candidates and the expansion of Ingenium's growing presence in the United States. Prior to joining the company, Dr. Freedman supported Ingenium in the capacity of an expert in drug discovery and development. Previously, Dr. Freedman was Senior Vice President, Head of Global Research for Elan Pharmaceuticals and held a number of management positions at Merck & Co., Inc.

"Stephen's 25 years of experience in leadership positions in biopharmaceutical and major pharmaceutical companies, as well as his expertise in Ingenium's therapeutic areas, will become a cornerstone for the next phase of Ingenium's evolution, namely bringing our programs closer to the clinic," stated Michael C. Nehls, M.D., Ph.D., CEO of Ingenium. "Stephen's commitment to the company and our management team is a strong endorsement of our growing pipeline and future potential."

"My past experience with Ingenium as a drug discovery partner to Elan, and in my recent function as an advisor to the company, provided me with a very close view of the value of the technology and the company's ability to advance exciting drug targets," added Dr. Freedman. "The progress Ingenium has achieved in the last year makes this an exciting time to join the company."

Dr. Freedman's pharmaceutical industry experience includes more than 10 years at Elan Pharmaceuticals, his last position being Senior Vice President, Head of Global Research at Elan's San Francisco site. Prior to Elan, Dr. Freedman spent over 12 years at Merck & Co., Inc. He received his Ph.D. in Pharmacology from the University of Southampton, England.

Ingenium Pharmaceuticals discovers and develops novel therapeutics to treat pain and chronic inflammatory diseases. The company is applying its expertise and understanding of drug target biology, in vivo pharmacology and medicinal chemistry to its growing portfolio of compounds and targets. Ingenium has partnerships and licensing agreements across the international biopharmaceutical industry. Based in Munich, Germany, Ingenium is financed by premier biotechnology-focused venture capital funds.

For more information contact: Michael Grau CFO Ingenium Pharmaceuticals AG +49-89-8565-2369

CONTACT: Michael Grau, CFO, Ingenium Pharmaceuticals AG, +49-89-8565-2369

Web site: http://www.ingenium-pharmaceuticals.com/